Portfolio

Circadian Therapeutics is developing a portfolio of products to treat diseases related to treat circadian rhythm disorders.

We are rapidly moving CT-1500, our initial product for Non-24, towards NDA/MAA.

We are researching other pathways and validating efficacy of lead candidate drugs in non-human disease models, and will license these products as they become clinic-ready.

Overview of product development status
Portfolio Overview

Therapeutics that treat the causes, not just the symptoms

Contact

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

contact@circadiantherapeutics.com

+44 (0) 1865 546581

Registered Office

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

Registered No 10283353.

PRIVACY POLICY

© Circadian Therapeutics 2018.
All rights reserved.

Website Design by Brand Cooke

Accessibility